Guggenheim Capital’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.44M Sell
6,346
-3,374
-35% -$1.9M 0.02% 559
2026
Q1
$5.76M Buy
9,720
+1,564
+19% +$779K 0.04% 412
2025
Q4
$3.97M Buy
8,156
+968
+13% +$451K 0.03% 489
2025
Q3
$3.01M Sell
7,188
-3,358
-32% -$1.13M 0.02% 574
2025
Q2
$3.03M Sell
10,546
-491
-4% -$147K 0.02% 537
2025
Q1
$3.4M Buy
11,037
+597
+6% +$205K 0.03% 515
2024
Q4
$3.68M Sell
10,440
-4,938
-32% -$1.82M 0.03% 498
2024
Q3
$5.51M Sell
15,378
-10,571
-41% -$3.57M 0.04% 498
2024
Q2
$8.27M Sell
25,949
-3,221
-11% -$852K 0.06% 358
2024
Q1
$6.7M Buy
29,170
+5,975
+26% +$1.35M 0.05% 453
2023
Q4
$5.1M Sell
23,195
-6,167
-21% -$1.42M 0.04% 523
2023
Q3
$6.63M Buy
29,362
+164
+0.6% +$37.8K 0.06% 403
2023
Q2
$6.45M Buy
29,198
+4,797
+20% +$1.06M 0.05% 442
2023
Q1
$5.46M Sell
24,401
-581
-2% -$143K 0.05% 492
2022
Q4
$6.95M Buy
24,982
+2,442
+11% +$616K 0.06% 405
2022
Q3
$4.72M Sell
22,540
-6,668
-23% -$1.49M 0.04% 522
2022
Q2
$6.88M Sell
29,208
-7,237
-20% -$1.47M 0.05% 420
2022
Q1
$6.54M Sell
36,445
-50
-0.1% -$9.53K 0.04% 549
2021
Q4
$7.89M Buy
36,495
+287
+0.8% +$56.3K 0.04% 509
2021
Q3
$6.68M Sell
36,208
-897
-2% -$177K 0.04% 540
2021
Q2
$6.66M Sell
37,105
-1,688
-4% -$321K 0.04% 558
2021
Q1
$6.49M Buy
38,793
+478
+1% +$79.7K 0.04% 519
2020
Q4
$5.82M Sell
38,315
-1,771
-4% -$232K 0.04% 519
2020
Q3
$4.05M Buy
40,086
+4,495
+13% +$493K 0.03% 615
2020
Q2
$4.31M Sell
35,591
-24,458
-41% -$2.75M 0.03% 583
2020
Q1
$5.69M Sell
60,049
-9,027
-13% -$858K 0.06% 398
2019
Q4
$6.08M Buy
69,076
+14,980
+28% +$1.32M 0.05% 526
2019
Q3
$4.31M Sell
54,096
-5,387
-9% -$434K 0.03% 665
2019
Q2
$4.64M Sell
59,483
-8,408
-12% -$786K 0.04% 648
2019
Q1
$7.97M Buy
67,891
+11,838
+21% +$1.38M 0.06% 380
2018
Q4
$6.1M Sell
56,053
-1,847
-3% -$214K 0.05% 464
2018
Q3
$7.4M Sell
57,900
-20,779
-26% -$2.57M 0.05% 486
2018
Q2
$8.9M Sell
78,679
-27,370
-26% -$3.01M 0.06% 379
2018
Q1
$11.9M Buy
106,049
+2,818
+3% +$358K 0.03% 618
2017
Q4
$15.3M Buy
103,231
+12,694
+14% +$1.61M 0.04% 577
2017
Q3
$10.6M Buy
90,537
+6,941
+8% +$886K 0.02% 658
2017
Q2
$10.8M Buy
83,596
+26,564
+47% +$3.31M 0.03% 648
2017
Q1
$7.72M Buy
57,032
+11,463
+25% +$1.74M 0.02% 780
2016
Q4
$6.54M Sell
45,569
-75,756
-62% -$9.67M 0.02% 864
2016
Q3
$14.3M Sell
121,325
-17,441
-13% -$2.1M 0.04% 565
2016
Q2
$14.7M Sell
138,766
-8,155
-6% -$910K 0.05% 560
2016
Q1
$16.4M Sell
146,921
-18,578
-11% -$2.35M 0.05% 575
2015
Q4
$25.9M Sell
165,499
-72,639
-31% -$10.6M 0.08% 474
2015
Q3
$31.3M Buy
238,138
+5,227
+2% +$838K 0.1% 366
2015
Q2
$40.5M Sell
232,911
-1,113
-0.5% -$200K 0.1% 352
2015
Q1
$40.4M Buy
234,024
+4,868
+2% +$742K 0.1% 380
2014
Q4
$29.7M Sell
229,156
-46,100
-17% -$5.94M 0.07% 484
2014
Q3
$35.4M Sell
275,256
-7,722
-3% -$796K 0.08% 386
2014
Q2
$25M Sell
282,978
-43,386
-13% -$4.17M 0.06% 558
2014
Q1
$30.7M Buy
326,364
+11,172
+4% +$1.14M 0.09% 369
2013
Q4
$35.6M Sell
315,192
-21,456
-6% -$1.93M 0.11% 243
2013
Q3
$26.5M Sell
336,648
-5,474
-2% -$400K 0.1% 281
2013
Q2
$22.5M Buy
+342,122
New +$22M 0.09% 279

Other funds holding UTHR

Guggenheim Capital's UTHR Position: Q2 2026 in Review

Guggenheim Capital reduced its United Therapeutics (UTHR) stake by 35% in Q2 2026, selling an estimated $1.9M and leaving 6,346 shares worth $3.44M. The position accounts for 0.02% of the portfolio, ranked #559.

Guggenheim Capital first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $40.5M in Q2 2015. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Guggenheim Capital held 6,346 shares of United Therapeutics worth $3.44M as of Q2 2026.
  • Guggenheim Capital sold 3,374 United Therapeutics shares in Q2 2026, an estimated $1.9M.
  • United Therapeutics made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #559 holding.
  • Guggenheim Capital first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Guggenheim Capital's United Therapeutics position peaked at $40.5M in Q2 2015.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.